Litcius/Paper detail

Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial

Andra Bălănescu, Gustavo Citera, Virginia Pascual‐Ramos, Deepak L. Bhatt, Carol A. Connell, David Gold, All‐shine Chen, Gosford Sawyerr, Andrea Shapiro, Janet Pope, Hendrik Schulze‐Koops

2022Annals of the Rheumatic Diseases68 citationsDOIOpen Access PDF

Topics & Concepts

MedicineTofacitinibRheumatoid arthritisInternal medicineOpen labelRandomized controlled trialTumor necrosis factor alphaArthritisAntirheumatic AgentsSurgeryClinical trialRheumatoid factorDermatologyRheumatoid Arthritis Research and TherapiesSpondyloarthritis Studies and TreatmentsStreptococcal Infections and Treatments
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial | Litcius